Mergers and acquisitions are of major importance in the pharmaceutical industry. In order to evaluate the dynamics of this particular industry, this paper critically evaluates the pre- and post- merger situation of GlaxoSmithKline concerning its ready-access to markets, know-how and management capability. Furthermore, strengths and weaknesses and merger’s outcomes will be outlined. Critical push and pull factors affecting M&A activity in North America will be analysed, using Pfizer and Pharmacia as an example. In addition, general reasons for M&A failure in the pharmaceutical industry will be illustrated focussing on the M&A activity of GlaxoSmithKline. Finally, using two global pharmaceutical players (GSK and Astrazeneca), the merits and demerits of the McKinsey’s five step programme will be discussed.
Table of Contents
INTRODUCTION
QUESTION ONE
QUESTION TWO
QUESTION THREE
QUESTION FOUR
CONCLUSIONS AND RECOMMENDATIONS
Research Objectives and Themes
This assignment investigates the strategic dynamics of mergers and acquisitions (M&A) within the global pharmaceutical industry, using the formation of GlaxoSmithKline and the merger of AstraZeneca as primary case studies to evaluate performance outcomes and the validity of established management frameworks.
- The role of M&A in enhancing market access, technical know-how, and management capabilities.
- Push and pull factors driving consolidation within the North American pharmaceutical market.
- Identification of critical success and failure factors in large-scale pharmaceutical mergers.
- Critical assessment of the McKinsey five-step M&A programme in a real-world corporate context.
Excerpt from the Book
Merger failure in Pharmaceutical Industry
Pharmaceutical Industry relies on R&D (Buerkle, 1998). According to Porter (1998, p171), “the technological change itself lowers cost or enhances differentiation and the firm’s technological lead is sustainable”. A firm will get more interest if it can lower its cost on technologic innovation. It will enlarge its market share if its products are different from other forms. It will be on the leading role if it can protect its products from imitation. Pharmaceutical industry relies more on R & D and technological innovation than other industries such as clothing because pharmaceutical industry has an affect on people’s health and life. The consumers are likely to select those new and high- technological products for their health.
But merger might have some bad implication dragging off the efficiency of R & D. On the process of integration, the company has to increase bureaucracy which may reduce R&D. During the integration process, in order to make the staffs cooperate with each other, changes in policies and procedures in the labs are necessary, but they may also slowdown research. Effective teams are split up post-merger (Buerkle, 1998). Post-merger, the staff of the two enterprises have to be integrated. Some of the efficient research teams have to be split up, which will slowdown efficiency. Giant companies have to support a large bureaucracy thus increasing costs. Therefore, the product line may not be sustained.
Chapter Summaries
INTRODUCTION: Provides an overview of the global pharmaceutical industry, emphasizing its high profitability and research-driven nature, and outlines the paper's aim to analyze industry M&A activity.
QUESTION ONE: Critically evaluates the GlaxoSmithKline merger, examining how the consolidation of Glaxo Wellcome and SmithKline Beecham aimed to secure market access, knowledge transfer, and enhanced management capabilities.
QUESTION TWO: Explores the primary factors driving M&A activity in North America, highlighting the pressure to overcome new drug development droughts through economies of scale and marketing muscle.
QUESTION THREE: Discusses the inherent risks of mergers in the pharmaceutical sector and identifies common reasons for failure, such as cultural mishandling, leadership vacuums, and integration difficulties.
QUESTION FOUR: Applies the McKinsey five-step programme to the cases of AstraZeneca and GlaxoSmithKline to assess the effectiveness of each phase of the integration process.
CONCLUSIONS AND RECOMMENDATIONS: Summarizes the key findings, suggesting that successful M&A requires a stronger focus on cultural fit and human capital management rather than solely relying on financial strategies.
Keywords
Mergers and Acquisitions, Pharmaceutical Industry, GlaxoSmithKline, AstraZeneca, Research and Development, Corporate Strategy, SWOT Analysis, McKinsey Five-Step Programme, Market Access, Know-how, Management Capability, Integration, Strategic Management, Organizational Culture, Drug Innovation.
Frequently Asked Questions
What is the primary focus of this paper?
The paper focuses on analyzing mergers and acquisitions in the global pharmaceutical industry since the 1990s, using specific corporate examples to evaluate strategic outcomes.
What are the central themes of the research?
The research explores the impact of mergers on R&D efficiency, the influence of corporate culture on post-merger performance, and the drivers behind pharmaceutical consolidation.
What is the primary research question?
The work aims to critically evaluate whether M&As effectively resolve industry-wide challenges, such as the drought in new drug development and the need for increased market power.
Which methodology is used to conduct the analysis?
The study utilizes strategic management analysis, including SWOT frameworks, the Porter's Five Forces model, and the assessment of the McKinsey five-step programme.
What does the main body cover?
It details the pre- and post-merger situations of companies like GlaxoSmithKline and AstraZeneca, analyzes market trends in North America, and discusses reasons for merger failure.
Which keywords best characterize this work?
The work is characterized by terms such as Mergers and Acquisitions, R&D, Corporate Strategy, Organizational Culture, and Pharmaceutical Industry dynamics.
How does the merger of Glaxo Wellcome and SmithKline Beecham illustrate the risks of integration?
The merger highlights risks associated with clashing management philosophies and the loss of R&D efficiency due to increased bureaucracy and internal resistance to change.
In what way does the paper challenge the efficacy of the McKinsey five-step programme?
The authors argue that the McKinsey model is fundamentally flawed because it focuses heavily on financial and technical aspects while ignoring critical soft skills and personnel issues.
Why are mergers often considered a "preferred response" to industry challenges despite high failure rates?
Companies view them as a way to achieve economies of scale and secure a larger R&D budget, even though they often lead to the destruction of value and decreased productivity.
- Quote paper
- Mennen (Author), Abayomi (Author), Jian (Author), Mead (Author), Zhou (Author), 2006, Mergers and Acquisitions in the Global Pharmaceutical Industry, Munich, GRIN Verlag, https://www.grin.com/document/145495
